论文部分内容阅读
双(β-二酮络)钛(Ⅳ)类配合物是继顺铂用于临床后唯一进入抗肿瘤临床研究的非铂类过渡金属配合物。Keller于1981年首次报道双(β-二酮络)钛(Ⅳ)配合物有抗肿瘤活性,其中二乙氧基双(1-苯基-1,3-丁二酮络)钛(Ⅳ)(budotitane)和二氯化双(1-苯基-1,3-丁二酮络)钛(Ⅳ)的抗瘤活性最强。它们对S_(180)癌腹水型和实体型、Walker_(256)6癌、乙酰氧甲基亚硝胺(AMMN)诱导的结直肠癌、MAC 15A结肠癌均有明显活性,对L_(1210)和P_(388)白血病效果不明显。由于对实验性结直肠癌有明显抗瘤活性,而且毒副作用较小,无诱变性。故使该类化合物更具吸引力。
Bis (β-diketone) titanium (Ⅳ) complexes are the non-platinum-based transition metal complexes that cisplatin is the only one used clinically to study anticancer clinically. Keller reported for the first time in 1981 that bis (beta-diketo) titanium (IV) complexes have antitumor activity, of which titanium (IV) The highest antitumor activity of budotitane and bis (1-phenyl-1,3-butanedione) titanium (IV) dichloride was obtained. They showed significant activity on colorectal cancer S 180, ascorbic acid and solid type Walker 256 cancer, colorectal cancer induced by acetyloxy methyl nitrosamine AMMN, colorectal cancer MAC 15A, And P_ (388) leukemia effect is not obvious. Because of experimental colorectal cancer has obvious anti-tumor activity, and less side effects, no mutagenicity. Therefore, these compounds more attractive.